Niraparib Shrinks BRCA-Mutated Prostate Tumors.
Sign Up to like & getrecommendations! Published in 2019 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2019-030
Abstract: Niraparib showed promising signs of efficacy in the phase II GALAHAD trial of men with advanced prostate cancer whose tumors harbor mutations in the DNA damage-response pathway, especially among patients with gene defects in BRCA1… read more here.
Keywords: shrinks brca; prostate tumors; mutated prostate; niraparib shrinks ... See more keywords